TABLE 2.
MIC assessments with β-lactamase inhibitor combinations
| Drug | MIC (μg/ml) |
|||||
|---|---|---|---|---|---|---|
| AJ218 plus empty vector |
AJ218 ΔK35 ΔK36 plus empty vector |
|||||
| No inhibitor | Tazobactama | Avibactamb | No inhibitor | Tazobactama | Avibactamb | |
| Ampicillin | 8,192 | 4 | 4 | 8,192 | 1,024 | 32 |
| Cefazolin | 8 | 0.5 | 1 | 1,024 | 256 | 16 |
| Ceftazidime | 0.5 | 0.125 | 0.25 | 4 | 1 | 1 |
| Ceftriaxone | 0.0625 | 0.03125 | 0.0625 | 0.5 | 0.5 | 0.5 |
| Cefotaxime | 0.0625 | 0.03125 | 0.0625 | 0.5 | 0.5 | 0.5 |
| Imipenem | 0.5 | 0.25 | 0.25 | 0.5 | 0.25 | 0.5 |
| Meropenem | 0.03125 | 0.015625 | 0.03125 | 0.5 | 0.5 | 0.0625 |
| Ertapenem | 0.015625 | 0.008 | 0.015625 | 4 | 2 | 1 |
Tazobactam was used at a final concentration of 64 μg/ml.
Avibactam was used at a final concentration of 4 μg/ml.